Arrowhead Pharmaceuticals Statistics
Share Statistics
Arrowhead Pharmaceuticals has 124.43M shares outstanding. The number of shares has increased by 15.72% in one year.
| Shares Outstanding | 124.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 116.15M |
| Failed to Deliver (FTD) Shares | 2 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 9.39M, so 7.55% of the outstanding shares have been sold short.
| Short Interest | 9.39M |
| Short % of Shares Out | 7.55% |
| Short % of Float | 8.09% |
| Short Ratio (days to cover) | 9.41 |
Valuation Ratios
The PE ratio is -3.87 and the forward PE ratio is -5.1.
| PE Ratio | -3.87 |
| Forward PE | -5.1 |
| PS Ratio | 653.4 |
| Forward PS | 18 |
| PB Ratio | 12.51 |
| P/FCF Ratio | -3.84 |
| PEG Ratio | n/a |
Enterprise Valuation
Arrowhead Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.87B.
| EV / Earnings | -4.79 |
| EV / Sales | 808.97 |
| EV / EBITDA | -5.12 |
| EV / EBIT | -4.78 |
| EV / FCF | -4.75 |
Financial Position
The company has a current ratio of 6.74, with a Debt / Equity ratio of 0.63.
| Current Ratio | 6.74 |
| Quick Ratio | 6.74 |
| Debt / Equity | 0.63 |
| Total Debt / Capitalization | 38.76 |
| Cash Flow / Debt | -3.94 |
| Interest Coverage | -18.58 |
Financial Efficiency
Return on equity (ROE) is -3.23% and return on capital (ROIC) is -193.99%.
| Return on Equity (ROE) | -3.23% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -193.99% |
| Revenue Per Employee | 6.76K |
| Profits Per Employee | -1.14M |
| Employee Count | 525 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -2.77M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -23.57% in the last 52 weeks. The beta is 0.93, so Arrowhead Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | -23.57% |
| 50-Day Moving Average | 20.77 |
| 200-Day Moving Average | 24.11 |
| Relative Strength Index (RSI) | 50.08 |
| Average Volume (20 Days) | 1.40M |
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of $3.55M and earned -$599.49M in profits. Earnings per share was $-5.
| Revenue | 3.55M |
| Gross Profit | 3.55M |
| Operating Income | -601.08M |
| Net Income | -599.49M |
| EBITDA | -561.51M |
| EBIT | -601.08M |
| Earnings Per Share (EPS) | -5 |
Balance Sheet
The company has $102.69M in cash and $117.37M in debt, giving a net cash position of -$14.68M.
| Cash & Cash Equivalents | 102.69M |
| Total Debt | 117.37M |
| Net Cash | -14.68M |
| Retained Earnings | -1.63B |
| Total Assets | 1.14B |
| Working Capital | 592.30M |
Cash Flow
In the last 12 months, operating cash flow was -$462.85M and capital expenditures -$141.47M, giving a free cash flow of -$604.32M.
| Operating Cash Flow | -462.85M |
| Capital Expenditures | -141.47M |
| Free Cash Flow | -604.32M |
| FCF Per Share | -5.05 |
Margins
Gross margin is 100%, with operating and profit margins of -16.93K% and -16.88K%.
| Gross Margin | 100% |
| Operating Margin | -16.93K% |
| Pretax Margin | -16.96K% |
| Profit Margin | -16.88K% |
| EBITDA Margin | -15.81K% |
| EBIT Margin | -16.93K% |
| FCF Margin | -17.02K% |
Dividends & Yields
ARWR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -22.91% |
| FCF Yield | -22.26% |
Analyst Forecast
The average price target for ARWR is $39.5, which is 81% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.5 |
| Price Target Difference | 81% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Stock Splits
The last stock split was on Nov 17, 2011. It was a backward split with a ratio of 1:10.
| Last Split Date | Nov 17, 2011 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -1.31 |
| Piotroski F-Score | 3 |